The historical rank and industry rank for Taro Pharmaceutical Industries's EV-to-FCF or its related term are showing as below:
TARO'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.05 Med: 8.91 Max: 175.5
Current: 8.71
During the past 13 years, the highest EV-to-FCF of Taro Pharmaceutical Industries was 175.50. The lowest was -12.05. And the median was 8.91.
TARO's EV-to-FCF is ranked better than 82.39% of 511
companies
in the Drug Manufacturers industry
Industry Median: 22.95
vs TARO: 8.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Taro Pharmaceutical Industries's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taro Pharmaceutical Industries's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Taro Pharmaceutical Industries's EV-to-FCF falls into.
Taro Pharmaceutical Industries's current Enterprise Value is $749.4 Mil.
Taro Pharmaceutical Industries's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $86.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Taro Pharmaceutical Industries's PE Ratio for today is calculated as:
Taro Pharmaceutical Industries's share price for today is $42.45.
Taro Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Taro Pharmaceutical Industries EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TARO has been successfully added to your 